Vorasidenib is an orally bioavailable, brain-penetrant inhibitor of mutant isocitrate dehydrogenase-1 and -2, suppressing oncometabolite D-2-hydroxyglutarate generation with nanomolar potency to treat isocitrate dehydrogenase–mutant diffuse gliomas.
Usually ships within 24 hours.